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Posttraumatic stress disorder (PTSD) is a
severe condition resulting from exposure
to traumatic events, such as combat sit-
uations, sexual assault, serious injury or
the threat of death. Symptoms include dis-
turbing recurring flashbacks, avoidance or
numbing of memories of the event, and
hyperarousal, which continue for more
than a month after the traumatic event.
Reduced cortical GABA (Kugaya et al.,
2003) and cebrospinal fluid (CSF) allo-
pregnanolone levels (Rasmusson et al.,
2006) that positively and allosterically
modulate GABA action at GABAA recep-
tors (Belelli and Lambert, 2005) suggest
that in PTSD patients, a perturbation
of GABAergic neurotransmission plays a
role in the pathogenesis of this disorder.
Thus restoring downregulated brain allo-
pregnanolone levels may be beneficial in
treating PTSD.
There is a general consensus that mal-
adaptive fear responses (i.e., impaired fear
extinction) are a core feature of stress-
induced PTSD (Myers and Davis, 2007;
Maren, 2008). Exaggerated fear responses
and impaired extinction learning, or the
inability to extinguish fear memories, are
often treated with exposure-based ther-
apy (EBT), which involves the expo-
sure of the patient to the feared context
without any danger (Joseph and Gray,
2008). This closely approximates the pro-
cedure used to simulate and study fear
responses and fear extinction learning in
PTSDmousemodels (Marks, 1979).While
psychological therapy has been highly
effective both in treating PTSD and in
preventing the progression of the event
sequelae that leads to consolidation of
fear memories, one challenge of PTSD
therapy is the spontaneous recovery of fear
that often reemerges following successful
EBT.
For this reason, pharmacological treat-
ment may be advantageous alone or in
combination with EBT. Selective serotonin
reuptake inhibitors (SSRIs) are currently
the drugs of choice in treating PTSD.
They are effective in facilitating and restor-
ing the neurobiological changes altered in
PTSD patients, and they are devoid of the
unwanted side effects that plague the use of
benzodiazepines, more importantly, SSRIs
are potent therapeutics where benzodi-
azepines fail to be beneficial. Following
the observation that low non-serotonergic
doses of fluoxetine and congeners increase
allopregnanolone levels as their primary
mechanism of action, we suggested that
SSRIs acting as selective brain steroido-
genic stimulants (SBSSs) can improve dys-
functional emotional behavior and may be
of advantage in PTSD treatment. In addi-
tion to its use in PTSD, this novel steroido-
genic mechanism of action of SSRIs given
at low doses offers enormous therapeutic
potentials for the treatment of other psy-
chiatric disorders, including anxiety spec-
trum disorders, premenstrual dysphoria,
and probably depression, as these disor-
ders may be caused by a downregulation of
neurosteroid biosynthesis (Uzunov et al.,
1996; Westenberg, 1996; Guidotti and
Costa, 1998; Romeo et al., 1998; Uzunova
et al., 1998; Steiner and Pearlstein, 2000;
Berton and Nestler, 2006; Pinna et al.,
2006a, 2009; Pinna, 2010; Ipser and Stein,
2012; Pinna and Rasmusson, 2012; Lovick,
2013).
In vitro studies show that SSRIs
may activate 3α-hydroxysteroid dehy-
drogenase, thereby facilitating the
reduction of 5α-dihydroprogesterone
into allopregnanolone (Griffin and
Mellon, 1999). Nonetheless, the pre-
cise neuronal mechanisms involved in
the neurosteroidogenic action of SSRIs
remain unclear. Drug design welcomed
allopregnanolone biosynthesis as a target
for novel rapidly acting anxiolytics devoid
of sedation, tolerance, and withdrawal
liabilities (Rupprecht et al., 2009, 2010;
Schüle et al., 2011), and, in addition to
low doses of SSRIs, selective ligands for
the (18 kDa) translocase protein (TSPO),
which increase allopregnanolone levels,
may be beneficial in anxiety and PTSD
(Rupprecht et al., 2009).
A PTSD MOUSE MODEL
In our laboratory, we have used the socially
isolated (SI) mouse as a model char-
acterized by a downregulation of allo-
pregnanolone biosynthesis associated with
endophenotypic features of PTSD. The rel-
evance of the SI mice as a model of PTSD
lays in reproducing behavioral and neu-
rochemical alterations that are found in
PTSD patients (Pibiri et al., 2008). Thus, SI
mice express decreased corticolimbic allo-
pregnanolone levels in emotion-relevant
brain areas (frontal cortex, hippocam-
pus, basolateral amygdala) (Pibiri et al.,
2008; Pinna et al., 2008). The impulsivity
and violence of combat veterans (Forbes
et al., 2008), is matched in SI mice by
high levels of aggression (Pinna et al.,
2003). In PTSD patients, enhanced con-
textual fear and impaired fear extinction
learning was shown during re-exposure
to events that symbolize the triggering
traumatic event; however, cued fear was
not changed (Ameli et al., 2001; Rauch
et al., 2006). SI mice, analogously, display
exaggerated contextual fear and impaired
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fear extinction and unchanged cued fear
responses (Pibiri et al., 2008; Pinna et al.,
2008). Interestingly, PTSD patients fail
to respond to the pharmacological action
of benzodiazepine and show decreased
frontocortical benzodiazepine site bind-
ing (Bremner et al., 2000). Of note, SI
mice show a lack of sedative/anxiolytic
activity to diazepam and zolpidem (Pinna
et al., 2006b; Nin et al., 2011). In con-
trast, allopregnanolone or S-norfluoxetine
at low, non-SSRI active doses reduced
anxiety in SI mice, an effect that was
mimicked by allopregnanolone’s analog
ganaxolone (Pinna and Rasmusson, sub-
mitted). Interestingly, anxiolytic doses
of S-norfluoxetine also normalized the
immobility time of SI mice as determined
by the forced swim test (Nin et al., 2011).
Social isolation causes changes in the
frontocortical and hippocampus expres-
sion of GABAA receptor subunits. The cor-
tical expression of α1, α2, and γ2 subunit
mRNA was decreased by ≈50%, and α4
and α5 was increased by 130% in SI mice.
The expression α1 subunit mRNA in layer
I was decreased by 50% and unchanged in
layer V of SI mice (Pinna et al., 2006b).
Likewise, GABAAreceptor subunit expres-
sion of α1 was decreased and that of
α5 was increased in the hippocampus.
A downregulation of α1 (−40%) and an
increase in the expression of α5 subunit
proteins (+100%) was also determined
in SI mice. Because γ2 subunits are a
necessary prerequisite for the formation
of benzodiazepine-sensitive GABAA recep-
tors, our study suggests that the decrease
in γ2 expression and the lack of ben-
zodiazepine’s anxiolytic action observed
in SI mice may be a result of stress-
induced formation of benzodiazepine-
insensitive GABAA receptors strategically
integrated in circuitry that regulate anxi-
ety. Interestingly, we observed a decreased
benzodiazepine binding to hippocampal
synaptic membranes (Pinna et al., 2006b).
Unlike benzodiazepines, which have
a selective pharmacological profile and
fail to activate GABAA receptors con-
taining α4 and α6 subunits (Brown
et al., 2002), allopregnanolone modu-
lation of GABAA receptors exhibits a
broad pharmacological profile. Although
allopregnanolone acts preferentially on
δ subunit-containing GABAA receptors,
which confers neurosteroid sensitivity,
it also exerts effects on other GABAA
receptor subtypes at higher concen-
trations (Mihalek et al., 1999; Stell
et al., 2003). Thus, increasing corti-
colimbic allopregnanolone levels with
allopregnanolone injections or stimulat-
ing allopregnanolone biosynthesis with
S-norfluoxetine, or directly activation
of GABAA receptors with ganaxolone
likely improved anxiety because allopreg-
nanolone/ganaxolone acts on a larger
spectrum of GABAA receptor subunits.
Thus, allopregnanolone or analogs are
more advantageous than benzodiazepines
because they improve anxiety, fear, and
aggressiveness when benzodiazepines are
inactive. In addition, unlike benzodi-
azepines, allopregnanolone, ganaxolone,
or SBSS ligands may improve emotional
behavior at non-sedative concentrations
(Pinna et al., 2003, 2006b; Nelson and
Pinna, 2011; Nin et al., 2011; Pinna and
Rasmusson, submitted). These obser-
vations suggest that drugs designed to
selectively increase neurosteroidogenesis




A seminal observation by Uzunova et al.
(1998) suggested that SSRIs, includ-
ing fluoxetine and fluvoxamine might
be beneficial in the treatment of major
unipolar depression by increasing the
brain levels of allopregnanolone. This
SSRI-induced neurosteroidogenic effect
correlated with improved depressive
symptomatology and was confirmed by
several other reports in the field (Romeo
et al., 1998, reviewed in Pinna et al.,
2006a; Schüle et al., 2011). Previous
studies reported that SSRIs induce allo-
pregnanolone biosynthesis in rodent
brain slices following incubation with
the allopregnanolone’s precursor 5α-
dihydroprogesterone (Uzunov et al.,
1996). These observations were confirmed
in experiments in which fluoxetine’s abil-
ity to induce neurosteroidogenesis in
several corticolimbic structures was chal-
lenged using mouse models of psychiatric
disorders such as the SI mouse (Pinna
et al., 2003, 2004). Interestingly, fluoxe-
tine’s action as a steroidogenic stimulant
appeared to be the primary mechanism
of SSRIs: the drug concentrations, which
increased brain allopregnanolone levels
were less than, and dissociated from, those
effective as a selective serotonin reuptake
inhibitor, which justified a new name to
better define the “SSRI” mechanism of
action: selective brain steroidogenic stimu-
lants or SBSS (Pinna et al., 2006a, 2009).
The discovery of this novel mechanism
of action of SSRIs has stimulated drug
design to focus on the development of
new, more effective therapies for anxiety
disorders by targeting neurosteroidoge-
nesis. Novel neuronal biomarkers, for
the pharmacological target of neuros-
teroidogenesis as the next generation of
anxiolytic drugs, have been discovered
(Rupprecht et al., 2009). These include the
TSPO (Costa et al., 1994; Papadopoulos
et al., 2006), which represents the start-
ing point and an important rate-limiting
step in neurosteroidogenesis. TSPO reg-
ulates neurosteroidogenesis in the brain
by gating the entry of cholesterol into
the inner mitochondrial membranes of
glial cells, and its conversion into preg-
nenolone by P450scc Figure 1 (Costa
and Guidotti, 1991; Costa et al., 1994;
Papadopoulos et al., 2006; Rupprecht
et al., 2010). Pregnenolone can then be
taken up by pyramidal neurons (Costa
and Guidotti, 1991) where a cascade of
enzymatic processes takes place in the
cytosol resulting in the production of
neurosteroids, including pregnenolone
sulfate and allopregnanolone Figure 1.
Newmolecules that bind with high affinity
to TSPO have been recently investigated;
these drugs are able to exert important
anxiolytic effects but are devoid of the
unwanted side effects associated with ben-
zodiazepines, including over-sedation,
tolerance, and withdrawal symptoms
(Rupprecht et al., 2009, 2010). In mouse
models, TSPO agents have been shown
to potently increase allopregnanolone
levels in the hippocampus and cortex,
as well as to induce anxiolytic effects
(Kita et al., 2004). XBD173 and etifox-
ine have proven to be highly efficacious
anxiolytic and antidepressant drugs in a
number of behavioral tests (Rupprecht
et al., 2010; Schüle et al., 2011). The anx-
iolytic effects of these agents were related
to their ability to increase neurosteroid
biosynthesis upstream of allopregnanolone
synthesis within the neurosteroidogenic
cascade Figure 1, as confirmed by studies
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FIGURE 1 | Therapeutic strategies to increase neurosteroidogenesis and improve PTSD by
enhancing GABAergic neurotransmission. Depicted are three strategies to improve PTSD
symptoms by increasing corticolimbic allopregnanolone levels or by direct activation of GABAA
receptors. (A) TSPO ligands induce an upstream regulation of neurosteroidogenesis by gating the
entry of cholesterol into the inner mitochondrial membranes of glial cells, and its conversion into
pregnenolone. Pregnenolone can then be taken up by pyramidal neurons (Costa and Guidotti, 1991)
where a cascade of enzymatic processes takes place in the cytosol resulting in the production of
allopregnanolone. Interestingly, pregnenolone can be further sulfated to pregnenolone sulfate,
which has been described as both a positive NMDA receptor modulator (Kussius et al., 2009) and
negative GABAA receptor modulator (Mtchedlishvili and Kapur, 2003). (B) S-NFLX induces a
downstream activation of neurosteroidogenesis likely by stimulating allopregnanolone content at
the level of 3α-HSD (Griffin and Mellon, 1999). Neurosteroidogenesis is not globally expressed in
the brain but relies on rate-limiting step enzymes, which guard allopregnanolone availability and
thereby normalize its physiological levels in the required corticolimbic areas (e.g., after activation of
TSPO or after S-NFLX). Allopregnanolone, synthesized in glutamatergic cortical or hippocampal
pyramidal neurons, may improve PTSD symptoms after being secreted by an autocrine fashion and
act locally by binding post-synaptic or extra-synaptic GABAA receptors located on the same neuron
in which it was produced (arrow 1) (Agis-Balboa et al., 2006, 2007). Allopregnanolone may also
diffuse into synaptosome membranes of the cell bodies or dendritic arborization to attain
intracellular access to specific neurosteroid binding sites of GABAA receptors (arrow 2) (Akk et al.,
2005). (C) Allopregnanolone’s analogs (e.g., ganaxolone) directly activate GABAA receptors and are
beneficial in pathological conditions in which allopregnanolone biosynthesis is severely impaired.
TSPO, translocate protein (18 kDa); 5α-DHP, 5α-dihydroprogesterone; 5α-RI, 5α-reductase type I;
3α-HSD, 3α-hydroxysteroid dehydrogenase; S-NFLX, S-norfluoxetine.
in which key enzyme blockers for neuros-
teroid biosynthesis, including finansteride
and trilostane (Schüle et al., 2011), were
used. TSPO ligands (AC-5216/XBD173
and YL-IPA08) also improve PTSD-like
behavior in rodents in studies of sit-
uational reminders and contextual fear
responses (Qiu et al., 2013). In sum-
mary, these studies demonstrated the
neuropharmacological effects of several
TSPO agents, suggesting that TSPO may
represent a therapeutic target for drug
discovery. Thus, these drugs, which ful-
fill the requirements as SBSS molecules,
may be a new class of drugs for the future
treatment of PTSD and other anxiety dis-
orders. Consistently, TSPO ligands have
recently showed promising therapeutic
effects in clinical studies (Rupprecht et al.,
2010; Schüle et al., 2011).
The advantage of having a drug that
“indirectly” activates GABAA receptors
by increasing allopregnanolone levels
Figure 1 within the brain is that allopreg-
nanolone will not be globally increased.
Physiological concentrations of allopreg-
nanolone are unevenly expressed in the
brain (Pinna et al., 2000; Pibiri et al.,
2008), and regulated by rate-limiting step
enzymes such as 5α-reductase type I.
Pharmacological treatments also induce
a cell specific upregulation of brain
allopregnanolone, which is increased
in frontal cortex (pyramidal neurons,
5α-reductase is not expressed in interneu-
rons), hippocampus (CA1-3 pyramidal
neurons and dentate gyrus granular cells),
and basolateral amygdala (pyramidal-
like neurons) after fluoxetine but not
in striatum (where allopregnanolone is
produced in GABAergic long-projecting
neurons, spiny neurons) (Agis-Balboa
et al., 2006, 2007). Hence, while allo-
pregnanolone is downregulated during
social isolation, fluoxetine elevates its lev-
els in glutamatergic neurons but not in
GABAergic neurons (Nelson and Pinna,
2011). If allopregnanolone is administered
directly, it would be expressed all over
the brain and reach high levels in brain
regions where its levels are physiologically
lower.
Ideally, the SBSS drugs of the future
that selectively induce anxiolytic and anti-
PTSD effects, will be those molecules,
prototypic of fluoxetine, devoid of sero-
tonergic effects but capable of activating a
neurosteroidogenesis cascade downstream,
possibly stimulating allopregnanolone
content at the level of 5α-reductase
or 3α-hydroxysteroid dehydrogenase.
Understanding whether FLX’s action
on neurosteroidogenesis is mediated by
upregulating expression or function of 5α-
reductase is of pivotal importance because
this enzyme is downregulated in corticol-
imbic areas of SI mice and in post-mortem
frontal cortex (BA9) of depressed patients
(Agis-Balboa et al., submitted).
As an alternative, in patients
who cannot adequately synthesize
allopregnanolone and in whom admin-
istration of an SBSS is ineffective because
neurosteroidogenesis is greatly impaired,
the administration of an allopregnanolone
analog (Gulinello et al., 2003; Kaminski
et al., 2004), such as ganaxolone that
directly activates GABAA receptors
Figure 1 may offer a safe therapeutic alter-
native. A multisite Phase II trial of the
efficacy and safety of ganaxolone in PTSD
is currently under process.
CONCLUSION
Targeting allopregnanolone biosynthesis
with selective neurosteroidogenic agents
offers several therapeutic advantages: (1)
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allopregnanolone is not globally expressed
in the brain like in the case of administer-
ing allopregnanolone itself, in fact, using a
neurosteroidogenic molecule relies on the
stimulation of rate-limiting step enzymes
Figure 1, which guard allopregnanolone
levels and thereby normalize its physiolog-
ical levels in the required brain areas; and
(2) stimulating allopregnanolone biosyn-
thesis downstream of pregnenolone in the
neurosteroidogenic cascade circumvents
the production of several neurosteroids,
which by activating various neurotrans-
mitter systems may be associated with
unwanted side effects.
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